Projects
Search from 1157 projects:
1157 Project(s)
Intercept 747-303 NASH and OCA
Mar 7, 2016A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
Clinical Studies - Mar 7, 2016 - Mar 7, 2021
Automatically Closed
Project leader: Semela David
Members: Alfter Christine
Intercept 747-302 PBC und OCA
Mar 7, 2016“A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis”
Clinical Studies - Mar 7, 2016 - Mar 7, 2021
Automatically Closed
Project leader: Semela David
Members: Alfter Christine
SASl 36 The health burden of Primary Biliary Cirrhosis in Switzerland
Mar 7, 2016
Clinical Studies - Mar 7, 2016 - Sep 14, 2016
Completed
Project leader: Semela David
Members: Alfter Christine
Swiss Hepatitis B Cohort Study
Mar 7, 2016Swiss Hepatitis B Cohort Study
Fundamental Research - Mar 7, 2016 - Mar 7, 2016
Automatically Closed
Project leader: Semela David
Members: Alfter Christine, Zeuge Ulf
Evaluation der diagnostischen Genauigkeit und Sicherheit des Einsatzes bereits etablierter Ultraschall- und Magnetresonanz-Techniken (Elastographie, Multiparametrische Bildgebung) zur nicht-invasiven Diagnostik von Leber-/Milzerkrankungen im Vergleich zur simultanen perkutanen Leberbiopsie
Mar 7, 2016Evaluation CAP vs. Histologie Stephan Baumeler, Irina Bergamin Zusammenarbeit mit USZ Christoph Gubler und Michael Scharl
Clinical Studies - Mar 7, 2016 - Mar 7, 2020
Automatically Closed
Project leader: Semela David
Members: Alfter Christine
TICH-2: Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage
Mar 1, 2016Despite development of effective treatments for ischaemic stroke (thrombolysis, aspirin, hemicraniectomy) there is no proven effective treatment for spontaneous intracerebral haemorrhage (SICH). Trials conducted with treatments such as intesive blood...
Clinical Studies - Mar 1, 2016 - Mar 1, 2018
Completed
Project leader: Kägi Georg
Members: Vehoff Jochen
Merck EORTC 1325 / MK-3475-054 - Adjuvant immunotherapy with anti-PD-1 monoclonal anti-body Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A ran-domized, double- blind Phase 3 trial of the EORTC Mela-noma Group
Mar 1, 2016This is an international, double-blinded, placebo-controlled randomized phase III trial. Enrollment will be a multi-step process. Randomization (placebo vs. pembrolizumab) will be performed centrally and will be stratified for the following factors:...
Clinical Studies - Mar 1, 2016 - Mar 1, 2020
Automatically Closed
Project leader: Fehr Martin
PCG-2/UCA
Mar 1, 2016Randomized, double-blind, double-dummy, placebo-controlled, Phase III clinical trial on the efficacy and safety of a 12-weeks add-on treatment with LT-02 (gastro-resistant phosphatidylcholine granules) vs. placebo in patients with ulcerative colitis...
Clinical Studies - Mar 1, 2016 - Dec 31, 2017
Aborted
Members: Dora Barbara, Knellwolf Christina, Sulz Michael, Krieger-Grübel Claudia
SAKK 41/14 ACTIVE-2: PHYSICAL ACTIVITY IN PATIENTS WITH METASTATIC
Feb 23, 2016
Clinical Studies - Feb 23, 2016 - May 31, 2021
Automatically Closed
Project leader: Horber Daniel
BIOSIGNAL: Biomarker signature of stroke aetiology study
Feb 20, 2016In 25-39% der Fälle kann die Schlaganfall-Ursache trotz sorgfältiger Abklärungen nicht gefunden werden1. Diese Patienten können unter Umständen nicht einer adäquaten Sekundärprävention zugeführt werden. Dies ist insbesondere der Fall bei Patienten mi...
Clinical Studies - Feb 20, 2016 - Feb 20, 2018
Automatically Closed
Project leader: Kägi Georg
Single arm open label phase II pilot study of carboplatin in patients with metastatic castration-resistant prostate cancer (CRPC) and PTEN-loss and/or DNA repair defects. PRO-PLAT
Feb 17, 2016Clinical studies in unselected prostate cancer patients strongly support the hypothesis that platinums have anti-tumour activity in some patients with CRPC. For patients progressing after docetaxel based chemotherapy and a novel androgen receptor tar...
Clinical Studies - Feb 17, 2016 - Jan 1, 2019
Automatically Closed
Project leader: Omlin Aurelius
Escitalopram: Effects of serotonergic neuromodulation on behavioural recovery and motor network plasticity after cortical ischemic stroke: a longitudinal, placebo-controlled study
Feb 1, 2016This randomized, double blind, placebo-controlled longitudinal study encompassing behavioural, neurophysiological and neuroimaging endpoints is designed to test our hypothesis, based on results from our previous pilot study, that serotonergic neuromo...
Clinical Studies - Feb 1, 2016 - Feb 1, 2018
Completed
Project leader: Kägi Georg
A multicenter, randomized, double-blind, parallel-group,placebo-controlled variable treatment duration studyevaluating the efficacy and safety of Siponimod (BAF312)in patients with secondary progressive multiple sclerosisfollowed by extended treatment with open-label BAF312
Feb 1, 2016Extensionsstudie, Evaluation Sicherheit und Wirksamkeit von Siponimod bei sekundär progredienter MS.
Clinical Studies - Feb 1, 2016 - Feb 1, 2020
Automatically Closed
RESPECT ESUS: Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral q.d.) in patients with Embolic Stroke of undetermined Source
Jan 22, 2016There is uncertainty over the optimal stroke prevention treatment for patients with ESUS. The current treatment recommendations of ASA alone, sometimes given with clopidogrel or ticlopidine (P08-06684, P08-08481) are based on limited data. There is s...
Clinical Studies - Jan 22, 2016 - Jan 1, 2018
Automatically Closed
Project leader: Kägi Georg
Members: Vehoff Jochen, Mbialeu Suzie
Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial
Jan 20, 2016Dickdarmkrebs gehört zu den häufigsten bösartigen Tumoren weltweit. Die meisten Patienten mit Dickdarmkrebs unterziehen sich einer Operation. Trotz kompletter Entfernung des Dickdarmkrebs und eventuell zusätzlicher Chemotherapie ist jedoch das Risiko...
Clinical Studies - Jan 20, 2016 - Feb 1, 2028
Ongoing
Project leader: Gueller Ulrich
Abbvie M13-590 “A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection
Jan 2, 2016
Clinical Studies - Jan 2, 2016 - Mar 2, 2017
Completed
Project leader: Semela David
Members: Alfter Christine
Abbvie M13-594 A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Ribavirin in Adults with Chronic Hepatitis C Virus Genotype 3 Infection
Jan 2, 2016
Clinical Studies - Jan 2, 2016 - Mar 2, 2017
Completed
Project leader: Semela David
Members: Alfter Christine
Bone mineral density of the proximal humerus in patients with glenohumeral osteoarthritis : intraoperative assessment and impact on treatment alternatives
Jan 1, 2016The bone quality (bone mineral density - BMD) of the proximal humerus might be crucial for clinical outcome of some new and evolving shoulder arthroplasty systems like the stemless humeral components, which relies on uncemented pressfit fixation in t...
Fundamental Research - Jan 1, 2016 - Oct 1, 2017
Automatically Closed
Project leader: Jost Bernhard
Members: Zdravkovic Vilijam, Puskas Gabor, Kaufman Rolf
COBRA REDUCE - Cobra PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated with Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
Jan 1, 2016Hypothesis: In patients undergoing coronary intervention who are receiving oral anticoagulation, Cobra PzF stents with 14 days of DAPT after stenting provide superior outcomes versus Xience/Promus or Resolute drug-eluting stents with 6 months of DAPT...
Clinical Studies - Jan 1, 2016 - Mar 31, 2019
Completed
Project leader: Weilenmann Daniel
Members: Schneider Irene
Spire 1022
Jan 1, 2016Diese Studie dient dem Beleg der Überlegenheit von PF-04950615, einem PCSK9 Inhibitor, gegenüber einem Placebo bzgl. Risikoreduktion von kardiovaskulären Ereignissen bei Patienten mit sehr hohem kardiovaskulären Risiko und persistierend erhöhtem LDL-...
Clinical Studies - Jan 1, 2016 - Aug 31, 2017
Aborted
Project leader: Bilz Stefan
Members: Jenni Vera